VA
CLDX icon

Verdad Advisers’s Celldex Therapeutics CLDX Stock Holding History

Verdad Advisers’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$770K Buy
+20,704
New +$669K 0.74% 41

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verdad Advisers's CLDX Position: Q2 2026 in Review

Verdad Advisers opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 20,704 shares worth $770K. The stake represents 0.74% of the portfolio and ranks #41 among its holdings.

253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Verdad Advisers held 20,704 shares of Celldex Therapeutics worth $770K as of Q2 2026.
  • Celldex Therapeutics was a new Verdad Advisers position in Q2 2026.
  • Celldex Therapeutics made up 0.74% of Verdad Advisers's portfolio in Q2 2026, its #41 holding.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.